AU1103699A - Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia - Google Patents

Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia

Info

Publication number
AU1103699A
AU1103699A AU11036/99A AU1103699A AU1103699A AU 1103699 A AU1103699 A AU 1103699A AU 11036/99 A AU11036/99 A AU 11036/99A AU 1103699 A AU1103699 A AU 1103699A AU 1103699 A AU1103699 A AU 1103699A
Authority
AU
Australia
Prior art keywords
darpp
dephosphorylation
inhibitor
treating schizophrenia
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11036/99A
Inventor
Allen A. FIENBERG
Paul Greengard
Akinori Nishi
Gretchen L. Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/953,442 external-priority patent/US6013621A/en
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of AU1103699A publication Critical patent/AU1103699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU11036/99A 1997-10-17 1998-10-19 Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia Abandoned AU1103699A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08953442 1997-10-17
US08/953,442 US6013621A (en) 1997-10-17 1997-10-17 Method of treating psychosis and/or hyperactivity
US17401598A 1998-10-16 1998-10-16
US09174015 1998-10-16
PCT/US1998/022127 WO1999020273A1 (en) 1997-10-17 1998-10-19 Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia

Publications (1)

Publication Number Publication Date
AU1103699A true AU1103699A (en) 1999-05-10

Family

ID=26869782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11036/99A Abandoned AU1103699A (en) 1997-10-17 1998-10-19 Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia

Country Status (2)

Country Link
AU (1) AU1103699A (en)
WO (1) WO1999020273A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989362B1 (en) 1999-10-15 2006-01-24 The Rockefeller University Methods of treating dopamine dysregulation using agents that regulate phosphorylation/dephosphorylation in dopamine signaling
KR20040066788A (en) * 2001-08-31 2004-07-27 더 락커펠러 유니버시티 Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
CA2458968A1 (en) 2001-08-31 2003-03-13 The Rockefeller University Method for classification of anti-psychotic drugs
US7935500B2 (en) * 2002-03-26 2011-05-03 Massachusetts Institute Of Technology Identifying calcineurin activators for treatment of schizophrenia
WO2005113572A2 (en) * 2004-05-19 2005-12-01 Merck & Co., Inc. Isolated nucleic acid molecules encoding a novel phosphoprotein-darpp-32, encoded protein and uses thereof
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110011A (en) * 1994-06-13 2004-09-27 Yeda Res & Dev Pharmaceutical compositions for the treatment of schizophrenia
US5777195A (en) * 1996-05-17 1998-07-07 The Rockefeller University Knockout mutant mouse for DARPP-32 and use thereof

Also Published As

Publication number Publication date
WO1999020273A1 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
AU8140898A (en) Inhibitors of beta-lactamases and uses therefor
AU5100599A (en) Egf-genistein for prevention of restenosis
AU4908699A (en) Use of pit emulsions
AU1536799A (en) Bishydroxyureas as inhibitors of the 5-lipoxygenase
AU6741698A (en) Absorbent articles having removable components
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU4231197A (en) Hppd gene and inhibitors
AU2951299A (en) Disinfecting compositions and processes for disinfecting surfaces
AU1296099A (en) Methods and compositions for treating dermatoses
AU3441197A (en) 3-ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes
AU6257496A (en) Method for increasing the efficacy of an odor masking agent
PL340838A1 (en) Application of the renin-angiotensin system inhibitors
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU3107795A (en) Inhibitors of the benzamidine type
HU9802971D0 (en) The use of mmp inhibitors for the treatments of ocular angiogenesis
AU9016898A (en) Methods and compositions for treatment of restenosis
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
AU7492198A (en) Use of an odorant for treating headaches
AU5038299A (en) Process for the biocidal treatment of surfaces
AU3187595A (en) Compounds for the treatment of restenosis
SG71778A1 (en) Agent for reducing the substrate dependence of resist
AU5296796A (en) Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use
AU1103699A (en) Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase